In:
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, Computers, Materials and Continua (Tech Science Press), Vol. 20, No. 12 ( 2013-10-21), p. 571-577
Kurzfassung:
Constitutive NF-κB activation characterizes a subset of myeloid leukemia (ML) cells. Recent reports have indicated that DNA methyltransferase (DNMT) inhibitors are alternative candidates for the treatment of ML. However, the optimal use of DNMT as a chemotherapeutic agent against
ML has yet to be established. In this report, we examined the effect of the NF-κB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) and its combinational use with the DNMT inhibitor 5-azacytidine (AZA) in ML cell lines. DHMEQ alone induced cell death in ML cell lines with NF-κB activation, although the response varied among the cell lines. The addition of DHMEQ enhanced the effect of AZA on the viability and apoptosis induction of ML cell lines. The treatment of ML cell lines with AZA marginally induced NF-κB binding activity, although the treatment induced
NF-κB protein. These results indicate the potential usefulness of DHMEQ and its combinational use with AZA in the treatment of ML, although the molecular effect by AZA on the NF-κB pathway awaits further study.
Materialart:
Online-Ressource
ISSN:
0965-0407
DOI:
10.3727/096504013X13775486749371
Sprache:
Englisch
Verlag:
Computers, Materials and Continua (Tech Science Press)
Publikationsdatum:
2013
ZDB Id:
1114699-0
ZDB Id:
2044620-2
